{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"27.3","value":"5.6"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"17.6","value":"0.0"},{"groupId":"OG002","lowerLimit":"5.0","upperLimit":"21.0","value":"11.3"},{"groupId":"OG003","lowerLimit":"4.0","upperLimit":"32.7","value":"14.3"},{"groupId":"OG004","lowerLimit":"0.1","upperLimit":"21.9","value":"4.3"},{"groupId":"OG005","lowerLimit":"0.0","upperLimit":"24.7","value":"0.0"},{"groupId":"OG006","lowerLimit":"11.3","upperLimit":"55.2","value":"28.6"},{"groupId":"OG007","lowerLimit":"0.8","upperLimit":"21.4","value":"6.5"},{"groupId":"OG008","lowerLimit":"27.0","upperLimit":"46.1","value":"36.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"31"},{"groupId":"OG008","value":"105"}],"units":"Participants"}],"description":"Overall Response Rate was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): ≥30% decrease in the sum of the longest diameters of target lesions compared with baseline; Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest; diameter recorded or the appearance of one or more new lesions; Stable Disease: Neither PR or PD","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Pathologically proven diagnosis of biliary tract carcinoma","id":"OG000","title":"Biliary Tract Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of carcinoma of unknown primary site","id":"OG001","title":"Carcinoma of Unknown Primary Site Cohort"},{"description":"Patients with pathologically proven diagnosis of endometrial carcinoma","id":"OG002","title":"Endometrial Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of Ewing's Family of Tumors","id":"OG003","title":"Ewing's Family of Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of Germ Cell Tumors, excluding immature teratoma, or teratoma with malignant transformation.","id":"OG004","title":"Germ Cell Tumors Cohort"},{"description":"Patients with Pathologically proven diagnosis of Head and Neck Carcinoma. Salivary glands tumors were excluded.","id":"OG005","title":"Head and Neck Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of BRCA1/2-associated metastatic breast carcinoma","id":"OG006","title":"BRCA1/2-associated Metastatic Breast Carcinoma Cohort"},{"description":"Patients with Pathologically proven diagnosis of Neuroendocrine Tumors, grade 2 and 3 according to World Health Organization (WHO) classification.","id":"OG007","title":"Neuroendocrine Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of small cell lung cancer","id":"OG008","title":"Small Cell Lung Cancer Cohort"}],"paramType":"NUMBER","populationDescription":"Treated patients and with disease measurement","reportingStatus":"POSTED","timeFrame":"From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}